Effective combination of biotechnology and synthetic technology
Flexibility responding to volume and technologies
A variety of chiral
50 years experience
in small molecule field
Since the early 1970s, Kaneka has been manufacturing numerous specialty pharmaceutical targets using a combination of synthetic and biotechnology, with a specialty in chiral compounds. The 2018 addition of a Kaneka designed continuous flow system for use at commercial scale has expanded our technology offerings to the market, and is an excellent complement to our existing technology platform.
Launch of New Website